このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

HTG Molecular Diagnostics 過去の業績

過去基準チェック /06

HTG Molecular Diagnosticsの収益は年間平均-7.2%の割合で減少していますが、 Healthcare Services業界の収益は年間増加しています。収益は年間8.3% 28.2%割合で減少しています。

主要情報

-7.2%

収益成長率

48.0%

EPS成長率

Healthcare Services 業界の成長	1.7%
収益成長率	-28.2%
株主資本利益率	-4,246.9%
ネット・マージン	-324.3%
前回の決算情報	31 Mar 2023

Recent updates

These Analysts Think HTG Molecular Diagnostics, Inc.'s (NASDAQ:HTGM) Sales Are Under Threat

Mar 26

What Type Of Returns Would HTG Molecular Diagnostics'(NASDAQ:HTGM) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 20

HTG shares surge after upbeat 2020 revenue forecast

Jan 05

HTG Molecular Diagnostics announced 1:15 reverse stock split

Nov 23

HTG Molecular Diagnostics (HTGM) Investor Presentation - Slideshow

Nov 18

収支内訳

HTG Molecular Diagnostics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

OTCPK:HTGM.Q 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費
31 Mar 23	6	-20	14
31 Dec 22	6	-22	16
30 Sep 22	7	-22	18
30 Jun 22	8	-22	19
31 Mar 22	9	-19	18
31 Dec 21	9	-17	17
30 Sep 21	9	-16	17
30 Jun 21	8	-17	17
31 Mar 21	8	-20	17
31 Dec 20	9	-21	18
30 Sep 20	11	-21	19
30 Jun 20	14	-20	18
31 Mar 20	18	-19	19
31 Dec 19	19	-19	19
30 Sep 19	22	-17	19
30 Jun 19	21	-17	19
31 Mar 19	21	-16	19
31 Dec 18	22	-16	20
30 Sep 18	22	-16	20
30 Jun 18	21	-17	19
31 Mar 18	18	-19	19
31 Dec 17	15	-19	18
30 Sep 17	8	-23	17
30 Jun 17	6	-24	17
31 Mar 17	6	-25	17
31 Dec 16	5	-26	17
30 Sep 16	5	-26	17
30 Jun 16	5	-25	17
31 Mar 16	4	-25	16
31 Dec 15	4	-23	15
30 Sep 15	4	-22	14
30 Jun 15	4	-21	13
31 Mar 15	4	-19	11
31 Dec 14	3	-18	10
30 Sep 14	3	-16	9
30 Jun 14	2	-15	8
31 Mar 14	3	-14	8
31 Dec 13	2	-14	8

質の高い収益: HTGM.Qは現在利益が出ていません。

利益率の向上: HTGM.Qは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: HTGM.Qの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。

成長の加速: HTGM.Qの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: HTGM.Qは利益が出ていないため、過去 1 年間の収益成長をHealthcare Services業界 ( 8.6% ) と比較することは困難です。

株主資本利益率

高いROE: HTGM.Qは現在利益が出ていないため、自己資本利益率 ( -4246.92% ) はマイナスです。

HTG Molecular Diagnostics 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

HTG Molecular Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Recent updates

Nasdaq to Delist the Common Stock of HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc.(OTCPK:HTGM.Q) dropped from NASDAQ Composite Index

HTG Molecular Diagnostics, Inc.(NasdaqCM:HTGM) dropped from S&P TMI Index

Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer

HTG Molecular Diagnostics, Inc. Filed for Bankruptcy

HTG Molecular Diagnostics Receives Non-Compliance Notice From Nasdaq

HTG Molecular Diagnostics, Inc. to Highlight the Advantages of its Drug Discovery Engine at the 2023 Biotechnology Innovation Organization

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for Full Year 2022

HTG Molecular Diagnostics, Inc. has completed a Follow-on Equity Offering.

HTG Molecular Diagnostics, Inc. Receives Non-Compliance Notice From Nasdaq

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. announced that it has received $0.0001 million in funding

HTG Molecular Diagnostics Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Announces Board Changes

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

HTG Molecular Q2 GAAP loss per share widens, revenue down

HTG Molecular Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Price target decreased to US$3.25

HTG Molecular Diagnostics amends senior loan facility

HTG Molecular Diagnostics, Inc., Annual General Meeting, Aug 17, 2022

HTG Molecular Diagnostics, Inc. Releases Second Whitepaper for Its Transcriptome-Informed Approach to Drug Discovery

HTG Molecular Diagnostics Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

HTG Molecular Diagnostics, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$9.50

HTG Molecular Diagnostics, Inc. Expands Features of Proprietary HTG EdgeSeq Technology

Consensus revenue estimates fall by 16%

Full year 2021 earnings: EPS exceeds analyst expectations

HTG Molecular Diagnostics, Inc. Appoints Dr. Robert Spitale to Therapeutics Scientific Advisory Board

HTG Molecular Diagnostics, Inc. Appoints Christopher P. Kiritsy to Serve as Class I Director, Member of Audit Committee

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for the Full Year 2021

HTG Molecular Diagnostics, Inc. Completes HTP Product Next-Phase Development Milestone

Is HTG Molecular Diagnostics (NASDAQ:HTGM) Using Debt In A Risky Way?

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$1.12 loss in 3Q 2020)

Is HTG Molecular Diagnostics (NASDAQ:HTGM) Weighed On By Its Debt Load?

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.39 loss per share (vs US$1.30 loss in 2Q 2020)

HTG Molecular Diagnostics, Inc. Announces Commercial Launch and Immediate Availability of its HTG Transcriptome Panel

HTG Molecular Diagnostics, Inc. Announces Completion of Product Design Lock for the HTG Transcriptome Panel

HTG Molecular completes product design lock for planned transcriptome panel

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.27 loss in 1Q 2020)

Price target decreased to US$9.75

HTG Molecular Diagnostics, Inc. Reports Preliminary Financial Results for the First Quarter Ended March 31, 2021 and Full Year 2021

Full year 2020 earnings released: US$4.51 loss per share (vs US$7.60 loss in FY 2019)

Consensus forecasts updated

Price target decreased to US$11.75

These Analysts Think HTG Molecular Diagnostics, Inc.'s (NASDAQ:HTGM) Sales Are Under Threat

HTG Molecular Diagnostics, Inc. to Report Fiscal Year 2020 Results on Mar 25, 2021

HTG Concludes Feasibility Testing & Releases Second White Paper for its Planned Whole Transcriptome Panel Using HTG EdgeSeq Technology

New 90-day high: US$7.83

New 90-day high: US$7.27

HTG Molecular Diagnostics, Inc. Announces Resignation of Timothy B. Johnson as Executive Chairman and a Member of the Board of Directors

What Type Of Returns Would HTG Molecular Diagnostics'(NASDAQ:HTGM) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Price target lowered to US$9.25

New 90-day high: US$6.10

HTG shares surge after upbeat 2020 revenue forecast

New 90-day high: US$5.61

Analysts update estimates

HTG Molecular Diagnostics announced 1:15 reverse stock split

HTG Molecular Diagnostics (HTGM) Investor Presentation - Slideshow

過去基準チェック /06